Review of 1027 patients with newly diagnosed multiple myeloma

Mayo Clinic Proceedings

Volumn 78, Issue 1, 2003, Pages 21-33

  Kyle, Robert A ^a   Gertz, Morie A ^a   Witzig, Thomas E ^a   Lust, John A ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Fonseca, Rafael ^a   Rajkumar, S Vincent ^a   Offord, Janice R ^a   Larson, Dirk R ^a   Plevak, Matthew E ^a   Therneau, Terry M ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CALCIUM; CREATININE; IMMUNOGLOBULIN LIGHT CHAIN; SERUM ALBUMIN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CELL LABELING; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYPERCALCEMIA; IMMUNOELECTROPHORESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PLASMA CELL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; RADIOGRAPHY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0037216353     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.1.21     Document Type: Article

References (48)

1. National Center for Health Statistics. Vital Statistics of the United States, 1988. Vol 2. Mortality, Part A. Washington, DC: Public Health Service; 1991.
2. Kyle RA, Beard CM, O'Fallon WM, Kurland LT. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Clin Oncol. 1994; 12:1577-1583.
3. Kyle RA. Henry Bence Jones - Physician, chemist, scientist and biographer: a man for all seasons. Br J Haematol. 2001;115:13-18.
4. Kyle RA. Multiple myeloma: An odyssey of discovery. Br J Haematol. 2000;111:1035-1044.
5. Komgold L, Lipari R. Multiple-myeloma proteins III: The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins. Cancer. 1956;9:262-272.
6. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc. 1975;50:29-40.
7. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
8. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
9. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001;68:269-275.
10. Iowa Surveillance, Epidemiology, and End-Results SEER Registry. 1973-1998.
11. Mueller PS, Terrell CL, Gertz MA. Fever of unknown origin caused by multiple myeloma: A report of 9 cases. Arch Intern Med. 2002;162:1305-1309.
12. Suchman AL, Coleman M, Mouradian JA, Wolf DJ, Saletan S. Aggressive plasma cell myeloma: A terminal phase. Arch Intern Med. 1981;141:1315-1320.
13. Grosbois B, Jego P, Attal M, et al. Familial multiple myeloma: Report of fifteen families. Br J Haematol. 1999;105:768-770.
14. Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines: Relevance to cancer and aging. Hematol Oncol Clin North Am. 2000;14:45-61.
15. Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRIAL(+) highly malignant plasma cells: A major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002;99:1305-1313.
16. Cavo M, Galieni P, Gobbi M, et al. Nonsecretory multiple myeloma: Presenting findings, clinical course and prognosis. Acta Haematol. 1985;74:27-30.
17. Rubio-Felix D, Giralt M, Giraldo MP, et al. Nonsecretory multiple myeloma. Cancer. 1987;59:1847-1852.
18. Dreicer R, Alexanian R. Nonsecretory multiple myeloma. Am J Hematol. 1982;13:313-318.
19. Bladé J, Kyle RA. Multiple myeloma in young patients: Clinical presentation and treatment approach. Leuk Lymphoma. 1998;30: 493-501.
20. Lacy MQ, Gertz MA, Hanson CA, Inwards DJ, Kyle RA. Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol. 1997;56:288-293.
21. Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med. 1985;145:1451-1452.
22. Kusumoto S, Jinnai I, Itoh K, et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J Haematol. 1997; 99:649-655.
23. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood. 1997;90: 2127-2147.
24. Greipp PR, Witzig TE, Gonchoroff NJ, et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 1987;62:969-977.
25. Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988; 72:219-223.
26. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am. 1999;13:1295-1314.
27. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology: An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501-2507.
28. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta 13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res. 2002;62:715-720.
29. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15:2659-2666.
30. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115: 931-935.
31. Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 1996;88:1780-1787.
32. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
33. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387.
34. Greipp PR, Leong T, Kay NE, VanNess BG, Oken MM, Kyle RA. From ECOG myeloma trial E9486: A prognostic index based on tumor burden, proliferation and host immune status [abstract]. Blood. 1997;90(suppl 1):350a.
35. Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley JJ. Beta 2 microglobulin (B2M) and albumin define a new staging system for multiple myeloma: The Southwest Oncology Group (SWOG) experience [abstract]. Blood. 2001;98:155a-156a.
36. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77:813-822.
37. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Français du Myelome. N Engl J Med. 1996;335:91-97.
38. Bladé J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol. 1996;14:2167-2173.
39. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484-489.
40. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
41. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-494.
42. Richardson PG, Berenson J, Irwin D, et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract]. Blood. 2001;98:774a.
43. Richardson PG, Schlossman RL, Hideshima T, et al. A phase I study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM) [abstract]. Blood. 2001;98:775a.
44. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract]. Blood. 2001;98:775a.
45. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.
46. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma. Blood. 2002;99:3163-3168.
47. Anderson KC. Multiple myeloma: Advances in disease biology: Therapeutic implications. Semin Hematol. 2001;38(suppl 3):6-10.
48. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Multiple myeloma. Hematol (Am Soc Hematol Educ Program). 2001;157-177.